From: Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma
Features | TCGA (n, %) | GSE30219 (n, %) | GSE31210 (n, %) | GSE3141 (n, %) | GSE81089 (n, %) |
---|---|---|---|---|---|
Platform | Illumina HiSeq2000 RNA sequencing platform | Affymetrix Human Genome U133 Plus 2.0 Array | Affymetrix Human Genome U133 Plus 2.0 Array | Affymetrix Human Genome U133 Plus 2.0 Array | Illumina HiSeq2000 RNA sequencing platform |
Age | |||||
≤ 60 y | 157 (31.4%) | 43 (50.6%) | 108 (47.8%) | – | 20 (18.5%) |
> 60 y | 333 (66.6%) | 42 (49.4%) | 118 (52.2%) | – | 88 (81.5%) |
NA | 10 (2.0%) | 0 (0.0%) | 0 (0.0%) | – | 0 (0.0%) |
Gender | |||||
Male | 230 (46.0%) | 66 (77.6%) | 105 (46.5%) | – | 39 (36.1%) |
Female | 270 (54.0%) | 19 (22.4%) | 121 (53.5%) | – | 69 (63.9%) |
NA | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | 0 (0.0%) |
Recurrence | |||||
Yes | 155 (31.0%) | 27 (31.8%) | 64 (28.3%) | – | – |
No | 285 (57.0%) | 58 (68.2%) | 162 (71.7%) | – | – |
NA | 60 (12.0%) | 0 (0.0%) | 0 (0.0%) | – | – |
AJCC stage | |||||
Stage I | 268 (53.6%) | – | 168 (74.3%) | – | 62 (57.4%) |
Stage II | 119 (23.8%) | – | 58 (25.7%) | – | 19 (17.6%) |
Stage III | 80 (16.0%) | – | 0 (0.0%) | – | 24 (22.2%) |
Stage IV | 25 (5.0%) | – | 0 (0.0%) | – | 3 (2.8%) |
Stage X | 8 (1.6%) | – | 0 (0.0%) | – | 0 (0.0%) |
T stage | |||||
T1 | 167 (33.4%) | 71 (83.5%) | – | – | – |
T2 | 267 (53.4%) | 12 (14.1%) | – | – | – |
T3 | 45 (9%) | 2 (2.4%) | – | – | – |
T4 | 18 (3.6%) | 0 (0.0%) | – | – | – |
TX | 3 (0.6%) | 0 (0.0%) | – | – | – |
N stage | |||||
N0 | 324 (64.8%) | 82 (96.5%) | – | – | – |
N1–3 | 165 (33.0%) | 3 (3.5%) | – | – | – |
NX | 11 (2.2%) | 0 (0.0%) | – | – | – |
M stage | |||||
M0 | 332 (66.4%) | 85 (100%) | – | – | – |
M1 | 24 (4.8%) | 0 (100%) | – | – | – |
MX | 144 (28.8%) | 0 (100%) | – | – | – |
Survival status | |||||
Alive | 318 (63.6%) | 40 (47.1%) | 191 (84.5%) | 26 (45.6%) | 59 (54.6%) |
Dead | 182 (36.4%) | 45 (52.9%) | 35 (15.5%) | 31 (54.4%) | 49 (45.4%) |